• Jaime G. de la Garza-SalazarEmail author
  • Paula Juarez-Sanchez


In 1970, in our Oncology Hospital in Mexico City, the majority of patients diagnosed with inflammatory breast cancer were dead after 12 months regardless of the treatment received; the treatment was local therapies with surgery and radiotherapy. We initiated, and probably and to our knowledge in the world, a new and different management of inflammatory breast cancer. The sequential treatment with primary chemotherapy, followed by surgery and radiotherapy, has improved disease-free and overall survival rates in patients treated with combined modality regimens. There are no data that consider an optimal chemotherapeutic regimen. Anthracycline-based regimen followed by local therapy reported 5- and 10-year survival rates of 40 and 33 %, respectively; the incorporation of taxanes has also shown to be associated with higher pCR and better survival. HER2-positive disease is associated with higher pCR rates; to anthracycline-based chemotherapy, the addition of trastuzumab significantly improved pathological complete responses and free survival. Therapies that target vascular–lymphatic processes have shown potential in the treatment of IBC, as represented by bevacizumab. Currently, there are no data to support the use of additional adjuvant chemotherapies in patients with residual disease. The epidemiology of inflammatory breast cancer (IBC) research has been interfered by the small number of publications reported.


Breast Cancer Survival Inflammatory Breast Carcinoma Inflammatory Breast Carcinoma Genomic Grade Index Primary Systemic Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Cristofanilli M, Buzdar A, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8:141–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Haagensen C. Diseases of the breast, 3rd ed. Philadelphia: WB Saunders, 1986:663.Google Scholar
  3. 3.
    Hansen KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–75.CrossRefGoogle Scholar
  4. 4.
    SEER cancer statistics were updated on 10 Nov 2011. NCI. USA.Google Scholar
  5. 5.
    Boussen H, Bouzaiene H, Ben Hassouna J, et al. Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. Cancer. 2010;116:2730–5.PubMedCrossRefGoogle Scholar
  6. 6.
    American Joint Committee on Cancer (AJCC) 7th Edition of Cancer Staging Manual, October 14, 2009.Google Scholar
  7. 7.
    Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2010. doi: 10.1093/annonc/mdq345.
  8. 8.
    Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological or a clinical and pathological definition? Int J Cancer. 1995;62:382.PubMedCrossRefGoogle Scholar
  9. 9.
    Cristofanilli M, Buzdar AU, et al. The evaluation of p53, HER2/neu, and serial MDR protein expression as possible markers of chemoresistance and their use as prognostic markers in inflammatory breast cancer. (Abstract). Proc Am Soc Clin Oncol. 1998;17:553a.Google Scholar
  10. 10.
    Aziz SA, Pervez S, Khan S, et al. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: unique clinical experience. Breast J. 2001;7:398–404.PubMedCrossRefGoogle Scholar
  11. 11.
    Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci. 2000;910:121–37.PubMedCrossRefGoogle Scholar
  12. 12.
    Moll UM, LaQuaglia M, Benard J, et al. Wild type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA. 1995;92:4407–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002;27:462–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Ann WG, Chuman Y, Fojo T, et al. Inhibitors of transcription proteasome inhibitors and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res. 1998;244:54–60.CrossRefGoogle Scholar
  15. 15.
    Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001;3:289–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Kleer CG, van Golen KL, Braun T, et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001;14:458–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61:5231–41.PubMedGoogle Scholar
  18. 18.
    Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastases. Nature. 2001;410:50–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Kijowski J, Baj-Kryzworzeka M, Majka M, et al. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not effect proliferation and survival in lymphohematopoietic cells. Stem Cells. 2001;19:453–66.PubMedCrossRefGoogle Scholar
  20. 20.
    Bachelder R, Wendt M, Mercurio A. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62:7203–6.PubMedGoogle Scholar
  21. 21.
    Cabioglu N, Summy J, Miller C, et al. CXCL-12/stromal cell-derived factor-1 alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 2005;65:6493–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol. 2007;18:1021–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast. 2004;13:97–103.PubMedCrossRefGoogle Scholar
  25. 25.
    Sawaki M, Ito Y, Akiyama F, et al. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer. 2006;13:172–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Troester MA, Lee MH, Carter M, et al. Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res. 2009;15:7020–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Van Laere S, Beissbarth T, Van der Auwera I, et al. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clin Cancer Res. 2008;14:7452–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Van Laere S, Van der Auwera I, Van den Eynden GG, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005;3:237–46.CrossRefGoogle Scholar
  29. 29.
    Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Cristofanilli M, González-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer. 2004;4:415–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 trial. Cancer. 2006;107:2535–44.PubMedCrossRefGoogle Scholar
  32. 32.
    Cheng YC, Rondon G, Yang Y, et al. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant. 2004;10:794–804.PubMedCrossRefGoogle Scholar
  33. 33.
    Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84.PubMedCrossRefGoogle Scholar
  34. 34.
    Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:474–84.PubMedCrossRefGoogle Scholar
  35. 35.
    Panades M, Olivotto IA, Speers CH. Evolving treatment strategies for inflammatory breast cancer. J Clin Oncol. 2005;23:1941–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Yamauchi H, Cristofanilli M, Nakamura S, et al. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol. 2009;6:387–94.PubMedCrossRefGoogle Scholar
  37. 37.
    Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769–77.PubMedCrossRefGoogle Scholar
  38. 38.
    Boussen H, Cristofanilli M, Zaks T, et al. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus placlitaxel in patients with inflammatory breast cancer. J Clin Oncol. 2010;28:3248–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Jaime G. de la Garza-Salazar
    • 1
    Email author
  • Paula Juarez-Sanchez
    • 2
  1. 1.Department of Clinical InvestigationInstituto Nacional de Cancerologia-MexicoTlalpan, Mexico CityMexico
  2. 2.Department of PathologyInstituto Nacional de Cancerologia-Mexico (INCan), SsaMexico CityMexico

Personalised recommendations